Six patients with rare blood disease are doing well after gene therapy clinical trial

UCLA researchers are part of an international team that reported the use of a stem cell gene therapy to treat nine people with the rare, inherited blood disease known as X-linked chronic granulomatous disease, or X-CGD. Six of those patients are now in remission and have stopped other treatments. Before now, people with X-CGD – which causes recurrent infections, prolonged hospitalizations for treatment, and a shortened lifespan – had to rely on bone marrow donations for a chance at remission.

Read more

GW Cancer Center Expands Clinical Trial Offerings for Patients with High Risk Cutaneous Squamous Cell Carcinoma

The Cutaneous Oncology Program at the GW Cancer Center was selected as the first global site for a clinical trial for patients with high-risk cutaneous squamous cell carcinoma. The study, sponsored by Regeneron, will examine outcomes for patients treated with Libtayo® (cemiplimab) — an immunotherapy treatment — prior to surgery and radiation therapy.

Read more

Partnership with China prompts change in care for high-risk type of leukemia

Researchers from St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated. The findings were reported today in JAMA Oncology.

Read more

Rutgers-led Team Launches Science and Medicine Research Initiative to Transform Health Care in New Jersey

At an event Thursday at Rutgers, thought leaders from academia, health care, government and the pharmaceutical industry discussed the future of scientific and clinical trial innovation in the state, as a result of an innovative consortium between Rutgers University, Princeton University and the New Jersey Institute of Technology.

Read more

Case report: Stem cells a step toward improving motor, sensory function after spinal cord injury

Stem cells derived from a patient’s own fat offer a step toward improving — not just stabilizing — motor and sensory function of people with spinal cord injuries, according to early research from Mayo Clinic.

Read more

CAR T Cell Clinical Trial for Non-Hodgkin’s Lymphoma Begins at Atlantic Health System

Atlantic Health System is treating patients in a new Phase 2 clinical trial of CAR T-cell therapy at Morristown Medical Center. A select number of sites across the U.S. are involved in this study, which is done on an outpatient basis. The study is sponsored by Juno Therapeutics, Inc. The study’s principal investigator, Mohamad Cherry, MD, medical director of hematology for Atlantic Health System Cancer Care, is a nationally known expert at treating and researching blood-related cancers such as lymphoma, leukemia and myeloma. Dr. Cherry is triple board-certified in internal medicine, hematology and medical oncology

Read more

Artificial Pancreas System Better Controls Blood Glucose Levels than Current Technology

Study based at the Icahn School of Medicine at Mount Sinai and other centers finds new system has safety, efficacy benefits for people with type 1 diabetes

Read more